# **Special Issue**

## Personalized Treatment in Cancer Research

## Message from the Guest Editors

In oncology, personalized medicine is an emerging approach for tumour therapy that takes into consideration the interindividual variability in treatment outcome and toxicity of each cancer patient. The personalization has the potential to tailor therapy towards the pharmacogenetics and pharmacokinetics drivers of treatment outcome and thus on patient quality of life. Furthermore, this could be the key to avoid suboptimal drug dosing or adverse events, taking into account the genetic variability of each person, their sex and their age. The Special Issue, "Personalized Treatment in Cancer Research", will focus on tailored treatment in cancer research, including clinical, preclinical, pharmacological and translational studies.

#### **Guest Editors**

Dr. Sarah Allegra

Department of Clinical and Biological Sciences, University of Turin, Torino, Italy

Dr. Silvia De Francia

Department of Biological and Clinical Sciences, University of Turin, S. Luigi Gonzaga Hospital, 10043 Turin, Italy

#### Deadline for manuscript submissions

closed (31 January 2025)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/141175

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





## **About the Journal**

## Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

#### Editor-in-Chief

#### Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

#### **Author Benefits**

### **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).